A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects

NCT01567683 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Imiquimod (topical use)

Sponsor

Moberg Pharma AB